Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Olaparib induces tumour response as single agent in BRCA-deficient breast cancer

Dr Andrew Tutt - Breakthrough Breast Cancer Research Unit, Kings College London...

Olaparib induces tumour response as single agent in BRCA-deficient breast cancer ( Dr Andrew Tutt - Breakthrough Breast Cancer Research Unit, Kings College London, UK )

PARP inhibitor BS-201 plus chemotherapy: new option for triple-negative breast...

Dr Joyce O'Shaughnessy - Baylor-Charles A. Sammons Cancer Center, US

PARP inhibitor BS-201 plus chemotherapy: new option for triple-negative breast cancer ( Dr Joyce O'Shaughnessy - Baylor-Charles A. Sammons Cancer Center, US )

Therapeutic vaccine improves response rate and extends progression-free...

Dr Patrick Hwu - M.D. Anderson Cancer Center, US

Therapeutic vaccine improves response rate and extends progression-free survival in patients with metastatic melanoma ( Dr Patrick Hwu - M.D. Anderson Cancer Center, US )

Bortezomib based therapies for myeloma

Dr Paul Richardson - Hematologic Oncology Dept, Dana-Farber Cancer Institute

Bortezomib based therapies for myeloma ( Dr Paul Richardson - Hematologic Oncology Dept, Dana-Farber Cancer Institute )

Therapeutic cancer vaccine significantly prolongs disease-free survival for...

Dr Stephen Schuster - University of Pennsylvania School of Medicine, USA

Therapeutic cancer vaccine significantly prolongs disease-free survival for follicular lymphoma ( Dr Stephen Schuster - University of Pennsylvania School of Medicine, USA )

PARP inhibitors show promise for hard-to-treat breast cancers

Dr. Andrew Tutt - Breakthrough Breast Cancer Research Unit, Kings College...

PARP inhibitors show promise for hard-to-treat breast cancers ( Dr. Andrew Tutt - Breakthrough Breast Cancer Research Unit, Kings College London, UK )

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

Dr. Jacek Gronwald, International Hereditary Cancer Centre, Poland

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients ( Dr. Jacek Gronwald, International Hereditary Cancer Centre, Poland )

PSA/Prostate screening

Dr. Otis W. Brawley - Chief Medical Officer, ASCO

PSA/Prostate screening ( Dr. Otis W. Brawley - Chief Medical Officer, ASCO )

Cancer prevention strategies

Professor Peter Boyle, International Prevention Research Institute

Cancer prevention strategies ( Professor Peter Boyle, International Prevention Research Institute )

Zoledronic acid for treament of prostate cancer

Dr. Thomas W. Leonard, Chief Scientific Officer, Merrion Pharmaceuticals

Zoledronic acid for treament of prostate cancer ( Dr. Thomas W. Leonard, Chief Scientific Officer, Merrion Pharmaceuticals )

ASCO: Patient accrual in clinical trials

Steven K. Cheng, PhD - Oregon Health and Science University, Oregan, USA

ASCO: Patient accrual in clinical trials ( Steven K. Cheng, PhD - Oregon Health and Science University, Oregan, USA )

ASCO: Prophylactic creams and antibiotics reduce severe drug-related skin rash

Dr. Edith Mitchell, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

ASCO: Prophylactic creams and antibiotics reduce severe drug-related skin rash ( Dr. Edith Mitchell, Thomas Jefferson University, Philadelphia, Pennsylvania, USA )

More from ecancer